UNSPSC 51393704: Pelrinone hydrochloride

This classification denotes a phosphodiesterase inhibitor with the molecular formula C12H11N5O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51K948JB05, chemically known as 1,4-dihydro-2-methyl-4-oxo-6-((3-pyridylmethyl)amino)-5-pyrimidinecarbonitrile monohydrochloride but more generally known as pelrinone hydrochloride, which bears US NIH Compound Identifier 55919. Most nations, for tariff and trade purposes, schedule pelrinone hydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, PELRINONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Pelrinone hydrochloride bears US NLM identifiers UMLS ID C2983940 and NCI Concept Code C90920. SMILES: CC1[NH]C(C(C(=O)N1)C#N)NCC2CCCNC2.CL.

UNSPSC 51393704 Pelrinone hydrochloride is a Commodity code that does not reflect the actual state and local procurement activity tagged under it. The two recent opportunities posted under this code solicit Naloxone (an opioid antagonist) and pharmacy benefit management services — neither of which is pelrinone hydrochloride, a cardiac inotropic agent. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding for community health initiatives, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission concurrently issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity to establish relationships outside traditional pharmacy benefit manager channels. The code shows misalignment between its nominal scope and the work actually being solicited under it.

Geographic activity centers on Florida and Texas in the recent record, though the Texas RFI is exploratory rather than a committed procurement and does not indicate a specific response deadline beyond the April 3, 2026 information-gathering window. The Seminole County opportunity targets naloxone supply for public health use with a July 26, 2023 response deadline (note: the posted date and due date are inconsistent in the source, with conflicting 2023 and 2026 markers). The issuing-body mix spans a county health department and a state health and human services agency, but the code's nominal pharmaceutical scope appears divorced from recent solicitation activity. Firms pursuing work under this code should verify the actual commodity being procured in each opportunity notice before investing RFQ or RFP response effort.